Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 1,113 matching trials from the local directory fallback.
Filters: Intervention: ART Clear all
Active, not recruiting Phase 2 Interventional

A Study of Efgartigimod in Patients With IgG4-Related Disease

NCT07025330
View directory record Official record
Conditions
IgG4-related Disease
Interventions
Efgartigimod
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Aug 2, 2026, 4:15 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

NCT05609370
View directory record Official record
Conditions
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Interventions
Alcestobart, Bevacizumab or Bevacizumab biosimilar, Fluoropyrimidine (FP), Tislelizumab
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
30
States / cities
Anchorage, Alaska • Gilbert, Arizona • Cerritos, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Jul 31, 2026, 6:02 AM EDT
Active, not recruiting Phase 1 Interventional

CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy

NCT06973096
View directory record Official record
Conditions
Glioblastoma
Interventions
CART-EGFR-IL13Ra2 cells, Fludarabine + Cyclophosphamide combination, Rituximab or Rituximab biosimilar
Drug · Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2042
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 15, 2026, 7:28 PM EDT
Active, not recruiting Not applicable Interventional

The JenaValve ALIGN-AR LVAD Registry

NCT06594705
View directory record Official record
Conditions
Aortic Insufficiency, Aortic Regurgitation, Aortic Valve Disease, Aortic Valve Insufficiency, Left Ventricular Dysfunction
Interventions
JenaValve Trilogy Heart Valve System
Device
Lead sponsor
JenaValve Technology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Jul 28, 2026, 7:10 AM EDT
Active, not recruiting Not applicable Interventional

Bayer OA Knee Pain Pilot

NCT05349682
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
dynamic contrast enhanced MRI, geniculate artery embolization
Diagnostic Test · Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
25 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 14, 2026, 9:04 PM EDT
Active, not recruiting Phase 1 Interventional

GFRα4 CAR T Cells in MTC Patients

NCT04877613
View directory record Official record
Conditions
Metastatic Medullary Thyroid Cancer, Recurrent Thyroid Gland Medullary Carcinoma
Interventions
Cyclophosphamide, Fludarabine, single dose of CART-GFRa4 cells
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2039
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 15, 2026, 3:58 AM EDT
Active, not recruiting Not applicable Interventional

A Randomized Trial to Assess Patient Quality of Life and Function After Alternative Surgeries for Pathologic Fractures of the Femur

NCT02164019
View directory record Official record
Conditions
Proximal Femoral Metastases
Interventions
intramedullary nailing (IMN), long-stem cemented hemiarthroplasty (LSCH), questionnaires
Procedure · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
6
States / cities
Grand Rapids, Michigan • New York, New York • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 2, 2026, 8:22 PM EDT
Active, not recruiting Phase 2 Interventional

Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)

NCT05331144
View directory record Official record
Conditions
Cognitively Normal Older Adults, Family History of Dementia, Hypertension, Subjective Cognitive Decline
Interventions
Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine), PCP
Drug · Other
Lead sponsor
Rong Zhang
Other
Eligibility
60 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 14, 2026, 9:52 PM EDT
Active, not recruiting Phase 1 Interventional

Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity

NCT07523711
View directory record Official record
Conditions
Obesity, Overweight
Interventions
COC, Maridebart Cafraglutide
Drug
Lead sponsor
Amgen
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 17, 2026, 9:06 AM EDT
Active, not recruiting Phase 1 Interventional

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

NCT02143466
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer
Interventions
Part A - AZD9291 in combination with AZD6094, Part A - AZD9291 in combination with MEDI4736, Part A - AZD9291 in combination with continuous selumetinib (Asian subjects), Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects), Part A - AZD9291 in combination with intermittent selumetinib, Part B - AZD9291 in combination with AZD6094, Part B - AZD9291 in combination with MEDI4736, Part B - AZD9291 in combination with selumetinib, Part C - AZD6094 monotherapy (Japan only), Part C - AZD9291 in combination with AZD6094 (Japan only), Part D - AZD9291 in combination with AZD6094
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
6
States / cities
Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 2, 2026, 8:24 PM EDT
Active, not recruiting Not applicable Interventional

Acceptability of Mobile Applications (Apps) to Enhance Smoking Cessation in a Clinical Tobacco Treatment Program - A Pilot Study

NCT05038852
View directory record Official record
Conditions
Smoking Cessation, Tobacco
Interventions
smartphone applications
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Aug 6, 2026, 4:07 AM EDT
Active, not recruiting Phase 2 Interventional

Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases

NCT03856658
View directory record Official record
Conditions
Liver Metastases, Pancreatic Adenocarcinoma
Interventions
Floxuridine (FUDR), Heparinized Saline, Hepatic Artery Infusion Pump
Drug · Device
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 15, 2026, 12:16 PM EDT
Active, not recruiting Not applicable Interventional

Randomized Trial of ACT and a Care Management App in Primary Care-based Buprenorphine Treatment

NCT05039554
View directory record Official record
Conditions
Chronic Pain, Opioid-use Disorder
Interventions
Acceptance and commitment therapy, Treatment as Usual, Valera Smartphone Application
Behavioral · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 15, 2026, 11:49 AM EDT
Active, not recruiting Phase 3 Interventional

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

NCT03778957
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Bevacizumab, Durvalumab, Placebo, Transarterial Chemoembolization (TACE)
Drug · Other · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 110 Years
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
24
States / cities
Costa Mesa, California • La Jolla, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 15, 2026, 3:13 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Support Your Heart, Phase 1

NCT07623733
View directory record Official record
Conditions
Cardio Vascular Disease, Diet, Healthy, Nicotine, Obesity & Overweight, Physical Activity, Sleep
Interventions
Support Your Heart
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 39 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Aug 1, 2026, 10:49 PM EDT
Active, not recruiting No phase listed Observational

On-X Aortic Prosthetic Heart Valve Low Dose Warfarin Post Approval Clinical Registry Study

NCT02677974
View directory record Official record
Conditions
Thrombotic and Bleeding Events
Interventions
On-X Aortic Heart Valve replacement
Device
Lead sponsor
On-X Life Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
15
States / cities
Tucson, Arizona • Hartford, Connecticut • Indianapolis, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 27, 2026, 10:35 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Longitudinal Study of Neighborhood Social Event Attendance at Renovated Parks and Changes in Sleep, Stress, and Well-being

NCT07699588
View directory record Official record
Conditions
Loneliness, Mental Health, Mood, Quality of Life, Sleep, Stress (Psychology), Well-being
Interventions
Community Park Event Participation
Behavioral
Lead sponsor
City University of New York, School of Public Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Aug 1, 2026, 6:03 PM EDT
Active, not recruiting Phase 1 Interventional

huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer

NCT05057715
View directory record Official record
Conditions
Pancreatic Cancer, Serous Ovarian Cancer
Interventions
VCN-01, huCART-meso Cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2038
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 8, 2026, 8:10 PM EDT
Active, not recruiting No phase listed Observational

Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study

NCT04431479
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Biospecimen Collection, Medical Chart Review, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Gainesville, Florida • Tampa, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 16, 2026, 9:41 AM EDT
Active, not recruiting Phase 1 Interventional

Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma

NCT03549442
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BCMA CART + huCART19, CART BCMA or CART BCMA + huCART19, Single-dose infusion of CART BCMA or CART BCMA + huCART19
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 15, 2026, 1:21 PM EDT
Active, not recruiting Phase 2 Interventional

Choline Supplementation as a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders Study

NCT05108974
View directory record Official record
Conditions
Fetal Alcohol Spectrum Disorders
Interventions
Choline Bitartrate
Drug
Lead sponsor
Jeff Wozniak
Other
Eligibility
30 Months to 72 Months
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 14, 2026, 5:16 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Seizure Rescue Medication (RM) as Part of a Comprehensive Epilepsy Self-management Package of Care

NCT06346262
View directory record Official record
Conditions
Epilepsy
Interventions
SMART RM, Valtoco Nasal Product
Behavioral · Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 30, 2026, 5:07 AM EDT
Active, not recruiting Phase 1 Interventional

C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)

NCT03635632
View directory record Official record
Conditions
Phyllodes Breast Tumor, Refractory Neuroblastoma, Relapsed Ewing Sarcoma, Relapsed Neuroblastoma, Relapsed Osteosarcoma, Relapsed Rhabdomyosarcoma, Uveal Melanoma
Interventions
C7R-GD2.CART cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 74 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2038
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 15, 2026, 12:13 AM EDT
Active, not recruiting Phase 3 Interventional

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

NCT06578247
View directory record Official record
Conditions
Leukemia
Interventions
Chemotherapy, Placebo, Quizartinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 70 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
52
States / cities
Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 21, 2026, 6:55 PM EDT